Electromedical Technologies, Inc. (EMED) presents a deeply negative liquidation posture as of September 30, 2024. Total assets of $569K stand against total liabilities of $4.57M, producing a GAAP stockholders' deficit of -$4.0M. Under liquidation haircuts, the recovery picture is worse. Cash of $35K recovers at par. Accounts receivable of $7K recovers at ~$6.5K (90%). Prepaid expenses of $239K — the largest current asset — recover at zero under liquidation; this is primarily customer deposits paid to the company's new product development vendor and other prepaid items with no liquidation value. Inventory of $24K recovers at ~$14.5K (60%). PP&E gross of $175K less accumulated depreciation of $25K gives net book value of $150K, primarily production tooling capitalized in 2023; at a 50-60% liquidation haircut on gross, recovery is approximately $87-105K, though tooling for a bespoke medical device has uncertain third-party marketability. The right-of-use asset of $114K has zero liquidation value. Total haircutted asset recovery is approximately $145-165K against $4.57M of face-value liabilities — a recovery deficit of roughly -$4.1M to -$4.4M, consistent with MFFAIS CLV/LLV estimates of approximately -$4.4M. The liability stack is dominated by: (1) $1.39M current convertible notes, several of which are in default or recently settled under debt modification agreements with maturity extended to September 2025; (2) $1.26M derivative liability on convertible notes, classified as Level 3 fair value using a Lattice model with implied stock volatility of 99.5-268% and market price $0.0005-$0.0050 — in liquidation this extinguishes only if underlying notes are settled, it does not recover to equity; (3) $764K customer deposits (ContractWithCustomerLiabilityCurrent) collected for the unreleased Wellness Pro Infinity product — these are refundable obligations in a liquidation scenario and rank ahead of equity at face value; (4) $131K ASC 842 operating lease liability across a lease running through September 2026. A separate $300K product development commitment is disclosed in MD&A (with ~$150K milestone-triggered and the balance tied to future product sales); this is not separately XBRL-tagged and would constitute an additional obligation in wind-down. The company has $25M in accumulated net losses, a going-concern qualification, a working capital deficit of $3.79M, and is burning cash operationally ($80K used in operations for nine months ended 9/30/24). Post-period debt-to-equity conversions continue, with $60K of principal converted into 120M shares post-9/30/24, accelerating dilution. Compared to the prior filing (10-Q for period ended 6/30/2024), the derivative liability increased materially (from approximately $532K at inception of the quarter to $1.26M at 9/30/24, driven by $678K unfavorable fair value change and $166K new issuances less $117K settlements). Customer deposits grew by $567K during the nine months (from zero at 12/31/23 to $764K), shifting a cash inflow from a credit positive to a face-value liability. The $150K long-term loan (OtherLoansPayableLongTerm) and $61K sales tax payable add to the non-convertible liability stack. Filing discusses the $300K product development commitment and approximately $72K in accrued default penalties for the Jefferson Street note in MD&A but neither item is separately tagged in XBRL at the balance-sheet line level.
▼ Community Notes